ARTICLE
23 September 2021

COVID-19 Key EU Developments, Policy & Regulatory Update No. 59

JD
Jones Day

Contributor

Jones Day is a global law firm with more than 2,500 lawyers across five continents. The Firm is distinguished by a singular tradition of client service; the mutual commitment to, and the seamless collaboration of, a true partnership; formidable legal talent across multiple disciplines and jurisdictions; and shared professional values that focus on client needs.
This regular update (no. 59 | 16 August 2021) covers key regulatory EU developments related to the evolving COVID-19 situation (Antitrust & State Aid; Trade/Export Controls; Medicines, Medical Devices...
European Union Coronavirus (COVID-19)
Kaarli H. Eichhorn’s articles from Jones Day are most popular:
  • within Coronavirus (COVID-19) topic(s)
  • in European Union
  • in European Union
  • in European Union
  • in European Union
Jones Day are most popular:
  • within Coronavirus (COVID-19), Strategy and Accounting and Audit topic(s)

This regular alert covers key regulatory EU developments related to the COVID-19 situation. It does not purport to provide an exhaustive overview of developments and contains no analysis or opinion.

LATEST KEY DEVELOPMENTS

Competition & State Aid

  • European Commission approves new synthetic securitization product to support SMEs affected by the pandemic
  • European Commission distributes additional pre-financing under Recovery and Resilience Plans to 4 Member States
  • European Commission approves new and amended Member State measures to support the economy

Trade / Export Controls

  • European Commission issues expanded Guidance Note on providing COVID-19-related humanitarian aid in sanctioned environments
  • Latest Eurostat data – A rise in exports, imports, and intra-euro area trade as compared to June 2020

Medicines and Medical Devices

  • European Commission approves latest Advanced Purchase Agreement with Novavax for potential COVID-19 vaccine
  • EMA commences evaluating use of RoActemra in hospitalized adults with severe COVID-19

Cybersecurity, Privacy & Data Protection

  • No noteworthy developments for this issue

To read the full article, please click here.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

[View Source]

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More